Biogen (NASDAQ:BIIB) – Research analysts at Piper Jaffray raised their Q1 2018 earnings per share (EPS) estimates for Biogen in a research report issued on Friday, April 13th. Piper Jaffray analyst C. Raymond now anticipates that the biotechnology company will earn $6.00 per share for the quarter, up from their prior forecast of $5.85. Piper Jaffray has a “Buy” rating on the stock. Piper Jaffray also issued estimates for Biogen’s Q3 2018 earnings at $6.39 EPS and FY2018 earnings at $24.75 EPS.
Several other equities research analysts have also issued reports on BIIB. Sanford C. Bernstein set a $318.00 price target on Biogen and gave the company a “buy” rating in a report on Tuesday, April 10th. Canaccord Genuity set a $350.00 price target on Biogen and gave the company a “hold” rating in a report on Monday, April 9th. Mizuho set a $433.00 price target on Biogen and gave the company a “buy” rating in a report on Wednesday, April 11th. BidaskClub upgraded Biogen from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Jefferies Group reiterated a “hold” rating on shares of Biogen in a report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and twenty-one have assigned a buy rating to the stock. Biogen has an average rating of “Buy” and a consensus price target of $366.49.
Shares of Biogen stock opened at $265.39 on Monday. The stock has a market cap of $56,580.33, a PE ratio of 12.17, a PEG ratio of 1.47 and a beta of 0.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. Biogen has a 52-week low of $244.28 and a 52-week high of $370.57.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.44 by ($0.18). The firm had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.04 earnings per share.
In other Biogen news, EVP Alfred Sandrock sold 1,294 shares of Biogen stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $298.85, for a total value of $386,711.90. Following the transaction, the executive vice president now directly owns 7,296 shares of the company’s stock, valued at approximately $2,180,409.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 2,296 shares of company stock worth $678,993. Company insiders own 0.25% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. IFC Holdings Incorporated FL increased its position in Biogen by 4.1% in the 4th quarter. IFC Holdings Incorporated FL now owns 4,050 shares of the biotechnology company’s stock worth $1,293,000 after buying an additional 160 shares during the period. Cue Financial Group Inc. grew its holdings in shares of Biogen by 11.3% during the 4th quarter. Cue Financial Group Inc. now owns 1,628 shares of the biotechnology company’s stock worth $519,000 after purchasing an additional 165 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Biogen by 77.0% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 174 shares in the last quarter. Linscomb & Williams Inc. grew its holdings in shares of Biogen by 13.5% during the 4th quarter. Linscomb & Williams Inc. now owns 1,481 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 176 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its holdings in shares of Biogen by 7.2% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 2,634 shares of the biotechnology company’s stock worth $839,000 after purchasing an additional 177 shares in the last quarter. 88.93% of the stock is currently owned by institutional investors.
WARNING: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/16/biogen-to-post-q1-2018-earnings-of-6-00-per-share-piper-jaffray-forecasts-biib.html.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.